Statistics for Pembrolizumab 400 mg every 6 weeks as firstline therapy for advanced melanoma KEYNOTE555 Results from cohort B of an openlabel phase 1 stud
Total visits
| views | |
|---|---|
| Pembrolizumab 400 mg every 6 weeks as firstline therapy for advanced melanoma KEYNOTE555 Results from cohort B of an openlabel phase 1 stud | 1 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 1 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| Journal Article.pdf | 4 |